| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8234963 | International Journal of Radiation Oncology*Biology*Physics | 2009 | 6 Pages |
Abstract
Necrosis-rescuing HBOT should be given with caution in patients with locoregionally recurrent and then successfully salvaged head-and-neck cancers; if it cannot be omitted entirely, deferring HBOT 9 months or longer after cancer re-treatment may be prudent.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Hon-Yi M.D., Chih-Hung Ph.D., Dai-Wei M.D., Ph.D., Hsing-Lung M.D., Chun-Shu M.D., Yee-Min M.D., Ph.D.,